Primary Care Diabetes Prescriptions Cost UK Over £2 Million a Day
Prescriptions to manage diabetes in primary care in the UK cost the NHS an average of £2.2 million ($3.7 m) every day in 2013-14, according to a report from the Health and Social Care Information Centre (HSCIC).
Prescriptions to manage diabetes in primary care in the UK cost the NHS an average of £2.2 million ($3.7 m) every day in 2013-14, according to a report from the Health and Social Care Information Centre (HSCIC).
The report, Prescribing for Diabetes, also shows the Net Ingredient Cost (NIC) for managing diabetes was £803.1 million ($1,347 m) in 2013–14. This is a 5.1 per cent increase from £764.1 million in 2012–13 (£2.1 million per day on average) and a 56.3 per cent increase on £2005-06 (£1.4 million per day on average).
Almost 10 per cent (9.5 per cent) of the NHS’s total primary care drugs bill was spent on managing diabetes, revealing a continuous annual rise from 6.6 per cent in 2005–06.
THe HSCIC report shows that in primary care in 2013-14:
- There were 45.1 million prescription items for managing diabetes, an average of 123,610 items per day.
- Insulin items can be prescribed for both type 1 and type 2 diabetes and accounted for about one in seven items prescribed for diabetes.
- Seven out of ten diabetes prescription items were for anti diabetic drugs, which are prescribed only for type 2 diabetes.
- Diagnositic and monitoring devices made up the remainder of diabetes items prescribed and the majority of these were blood glucose testing strips.
- Costs of all three categories of diabetes drugs have increased from 2005-06 but in particular insulin items where the rise in spending was 11.6 per cent higher than the rise in items prescribed.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.